Redvax Overview
- Status
- Acquired/Merged
- Latest Deal Type
- M&A
Redvax General Information
Description
Operator of a biopharmaceutical company in Sweden. The company develops multi-component virus-like particles (VLPs) and other protein assemblies for vaccine development in the field of Cytomegalovirus (CMV).
Contact Information
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Office
- Wagistrasse 23
- Schlieren
- 8952 Zurich
- Switzerland
Redvax Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Merger/Acquisition | 05-Jan-2015 | Completed | Pre-Clinical Trials | |||
| 1. Early Stage VC | Completed | Startup |
Redvax Executive Team (1)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Christian Schaub | Managing Director |
Redvax Former Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Redalpine Venture Partners | Venture Capital | Minority | 000 0000 | 000000 0 |